The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments
This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2008-04, Vol.23 (2), p.192-201 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 201 |
|---|---|
| container_issue | 2 |
| container_start_page | 192 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 23 |
| creator | Kersemans, Veerle Vergote, Valentijn de Gelder, Virginie Madani, Indira Thierens, Hubert De Neve, Wilfried Mertens, John Slegers, Guido Burvenich, Christian Peremans, Kathelijne De Spiegeleer, Bart |
| description | This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase.
In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with (60)Co gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [123I]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups.
The in vitro tests demonstrated that the [125I]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [123I]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the TUMOR-IRRADIATED GROUP, AS COMPARED TO THE CONTRALATERAL-IRRADIATED GROUP AND THE NOT-IRRADIATED CONTROL GROUP.
These findings in our cell and animal model systems indicate that [123I]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy. |
| doi_str_mv | 10.1089/cbr.2007.0362 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69170556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1473992521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-49c7e0ac44ef9432af126b336debdac28e6dd4814738ac4d7ee192e68dc8568c3</originalsourceid><addsrcrecordid>eNqF0U2L1TAUBuAgivOhS7cSXLjLNV9NUncyjM7AFUHGlUhJk1NuhzapSXuxf8NfbMq9ILhxlSwe3pyTF6FXjO4YNfU716Ydp1TvqFD8CbpkVaWJMRV_Wu7USFJrU12gq5wfKaWKKv0cXTAjK6mMuUS_Hw6Alww4dvg74-L-B-Gkjz6SPZkOENbBDjb0AbDN2AYMNg0rTtb3cT5AstOK4WiHxc59DHiOcXiP-4CP_Zwi_so-F9r6OK4x2-TiaLGDYShB_qSOEY9xex5-TZD6EcKcX6BnnR0yvDyf1-jbx9uHmzuy__Lp_ubDnjgh65nI2mmg1kkJXS0Ftx3jqhVCeWi9ddyA8l4aJrUwRXkNwGoOynhnKmWcuEZvT7lTij8XyHMz9nkbzwYoMzWqZppWlfovLN8vmWCmwDf_wMe4pFCWKEayurRCCyIn5FLMOUHXTGVxm9aG0WartCmVbpm62Sot_vU5dGlH8H_1uUPxB276nXk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204198520</pqid></control><display><type>article</type><title>The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kersemans, Veerle ; Vergote, Valentijn ; de Gelder, Virginie ; Madani, Indira ; Thierens, Hubert ; De Neve, Wilfried ; Mertens, John ; Slegers, Guido ; Burvenich, Christian ; Peremans, Kathelijne ; De Spiegeleer, Bart</creator><creatorcontrib>Kersemans, Veerle ; Vergote, Valentijn ; de Gelder, Virginie ; Madani, Indira ; Thierens, Hubert ; De Neve, Wilfried ; Mertens, John ; Slegers, Guido ; Burvenich, Christian ; Peremans, Kathelijne ; De Spiegeleer, Bart</creatorcontrib><description>This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase.
In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with (60)Co gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [123I]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups.
The in vitro tests demonstrated that the [125I]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [123I]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the TUMOR-IRRADIATED GROUP, AS COMPARED TO THE CONTRALATERAL-IRRADIATED GROUP AND THE NOT-IRRADIATED CONTROL GROUP.
These findings in our cell and animal model systems indicate that [123I]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/cbr.2007.0362</identifier><identifier>PMID: 18454688</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Animals ; Cell Line, Tumor ; Humans ; Mice ; Mice, Nude ; Myosarcoma - diagnosis ; Myosarcoma - metabolism ; Myosarcoma - radiotherapy ; Phenylalanine - analogs & derivatives ; Phenylalanine - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2008-04, Vol.23 (2), p.192-201</ispartof><rights>(©) Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-49c7e0ac44ef9432af126b336debdac28e6dd4814738ac4d7ee192e68dc8568c3</citedby><cites>FETCH-LOGICAL-c349t-49c7e0ac44ef9432af126b336debdac28e6dd4814738ac4d7ee192e68dc8568c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18454688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kersemans, Veerle</creatorcontrib><creatorcontrib>Vergote, Valentijn</creatorcontrib><creatorcontrib>de Gelder, Virginie</creatorcontrib><creatorcontrib>Madani, Indira</creatorcontrib><creatorcontrib>Thierens, Hubert</creatorcontrib><creatorcontrib>De Neve, Wilfried</creatorcontrib><creatorcontrib>Mertens, John</creatorcontrib><creatorcontrib>Slegers, Guido</creatorcontrib><creatorcontrib>Burvenich, Christian</creatorcontrib><creatorcontrib>Peremans, Kathelijne</creatorcontrib><creatorcontrib>De Spiegeleer, Bart</creatorcontrib><title>The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase.
In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with (60)Co gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [123I]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups.
The in vitro tests demonstrated that the [125I]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [123I]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the TUMOR-IRRADIATED GROUP, AS COMPARED TO THE CONTRALATERAL-IRRADIATED GROUP AND THE NOT-IRRADIATED CONTROL GROUP.
These findings in our cell and animal model systems indicate that [123I]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.</description><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Myosarcoma - diagnosis</subject><subject>Myosarcoma - metabolism</subject><subject>Myosarcoma - radiotherapy</subject><subject>Phenylalanine - analogs & derivatives</subject><subject>Phenylalanine - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0U2L1TAUBuAgivOhS7cSXLjLNV9NUncyjM7AFUHGlUhJk1NuhzapSXuxf8NfbMq9ILhxlSwe3pyTF6FXjO4YNfU716Ydp1TvqFD8CbpkVaWJMRV_Wu7USFJrU12gq5wfKaWKKv0cXTAjK6mMuUS_Hw6Alww4dvg74-L-B-Gkjz6SPZkOENbBDjb0AbDN2AYMNg0rTtb3cT5AstOK4WiHxc59DHiOcXiP-4CP_Zwi_so-F9r6OK4x2-TiaLGDYShB_qSOEY9xex5-TZD6EcKcX6BnnR0yvDyf1-jbx9uHmzuy__Lp_ubDnjgh65nI2mmg1kkJXS0Ftx3jqhVCeWi9ddyA8l4aJrUwRXkNwGoOynhnKmWcuEZvT7lTij8XyHMz9nkbzwYoMzWqZppWlfovLN8vmWCmwDf_wMe4pFCWKEayurRCCyIn5FLMOUHXTGVxm9aG0WartCmVbpm62Sot_vU5dGlH8H_1uUPxB276nXk</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Kersemans, Veerle</creator><creator>Vergote, Valentijn</creator><creator>de Gelder, Virginie</creator><creator>Madani, Indira</creator><creator>Thierens, Hubert</creator><creator>De Neve, Wilfried</creator><creator>Mertens, John</creator><creator>Slegers, Guido</creator><creator>Burvenich, Christian</creator><creator>Peremans, Kathelijne</creator><creator>De Spiegeleer, Bart</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments</title><author>Kersemans, Veerle ; Vergote, Valentijn ; de Gelder, Virginie ; Madani, Indira ; Thierens, Hubert ; De Neve, Wilfried ; Mertens, John ; Slegers, Guido ; Burvenich, Christian ; Peremans, Kathelijne ; De Spiegeleer, Bart</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-49c7e0ac44ef9432af126b336debdac28e6dd4814738ac4d7ee192e68dc8568c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Myosarcoma - diagnosis</topic><topic>Myosarcoma - metabolism</topic><topic>Myosarcoma - radiotherapy</topic><topic>Phenylalanine - analogs & derivatives</topic><topic>Phenylalanine - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kersemans, Veerle</creatorcontrib><creatorcontrib>Vergote, Valentijn</creatorcontrib><creatorcontrib>de Gelder, Virginie</creatorcontrib><creatorcontrib>Madani, Indira</creatorcontrib><creatorcontrib>Thierens, Hubert</creatorcontrib><creatorcontrib>De Neve, Wilfried</creatorcontrib><creatorcontrib>Mertens, John</creatorcontrib><creatorcontrib>Slegers, Guido</creatorcontrib><creatorcontrib>Burvenich, Christian</creatorcontrib><creatorcontrib>Peremans, Kathelijne</creatorcontrib><creatorcontrib>De Spiegeleer, Bart</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kersemans, Veerle</au><au>Vergote, Valentijn</au><au>de Gelder, Virginie</au><au>Madani, Indira</au><au>Thierens, Hubert</au><au>De Neve, Wilfried</au><au>Mertens, John</au><au>Slegers, Guido</au><au>Burvenich, Christian</au><au>Peremans, Kathelijne</au><au>De Spiegeleer, Bart</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>2008-04</date><risdate>2008</risdate><volume>23</volume><issue>2</issue><spage>192</spage><epage>201</epage><pages>192-201</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><abstract>This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase.
In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with (60)Co gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [123I]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups.
The in vitro tests demonstrated that the [125I]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [123I]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the TUMOR-IRRADIATED GROUP, AS COMPARED TO THE CONTRALATERAL-IRRADIATED GROUP AND THE NOT-IRRADIATED CONTROL GROUP.
These findings in our cell and animal model systems indicate that [123I]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>18454688</pmid><doi>10.1089/cbr.2007.0362</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 2008-04, Vol.23 (2), p.192-201 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69170556 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Cell Line, Tumor Humans Mice Mice, Nude Myosarcoma - diagnosis Myosarcoma - metabolism Myosarcoma - radiotherapy Phenylalanine - analogs & derivatives Phenylalanine - metabolism Xenograft Model Antitumor Assays |
| title | The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A30%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20%5B123I%5D-2-iodo-L-phenylalanine%20as%20an%20early%20radiotherapy%20evaluation%20tool:%20in%20vitro%20R1M%20rabdomyosarcoma%20cell%20and%20in%20vivo%20mouse%20experiments&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Kersemans,%20Veerle&rft.date=2008-04&rft.volume=23&rft.issue=2&rft.spage=192&rft.epage=201&rft.pages=192-201&rft.issn=1084-9785&rft.eissn=1557-8852&rft_id=info:doi/10.1089/cbr.2007.0362&rft_dat=%3Cproquest_cross%3E1473992521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=204198520&rft_id=info:pmid/18454688&rfr_iscdi=true |